Join Dr. Landgren as he discusses the progression from two- to three-drug regimens, the major clinical benefits of both, and the future direction of combination therapy.

Dr. Sagar Lonial discusses the need for SPEP, UPEP, and immunofixation testing in newly diagnosed multiple myeloma patients, in patients undergoing therapy, or in relapsed and refractory patients.

In this Managing Myeloma FAQ, Dr. Sagar Lonial discusses whether BD or KD should be considered a standard of care in relapsed/refractory multiple myeloma.

Join Dr. Giralt as he explains whether or not the new diagnostic criteria for multiple myeloma will cause confusion between risk of progression assessment and risk stratification for active myeloma.

In this Managing Myeloma FAQ, Dr. Sagar Lonial discusses the best indicator of improved outcomes in multiple myeloma: SCR, CR, IFCR, or MCR.

Join Paul Richardson, MD, in this Managing Myeloma FAQ as he describes true myeloma defining events and their impact on clinical practice.

Join Paul Richardson, MD, in this Managing Myeloma FAQ as he describes how to address medication compliance and adherence in the outpatient setting to oral medicines that we use in myeloma.

Join Paul Richardson, MD, in this Managing Myeloma FAQ as he briefly discusses the Revised International Staging System (R-ISS).

Join Robert Orlowski, MD, PhD in this brief Managing Myeloma FAQ as he discusses why a myeloma patient who has previous history of bone lesions should have a bone study as part of their CR assessment.

Join Dr. Sagar Lonial in this brief discussion regarding the emerging therapy classes for multiple myeloma.